Literature DB >> 15604432

Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology.

Xiaohong Wang1, Martin Sapp2, Neil D Christensen3, Joakim Dillner1.   

Abstract

The interaction between human papillomavirus (HPV) particles and cell surface heparan sulfate requires intact conformation of the HPV particles. Type-specific HPV serology is currently based on virus-like particles (VLPs) with intact conformation. Presence of incorrectly folded VLPs in VLP preparations is recognized as an important cause of cross-reactivity in HPV serology. Heparin-coated microtitre plates were evaluated for capturing conformationally correct VLPs and improving the type specificity of HPV serology. Hybrid VLPs between HPV16 and HPV11, which had been found to have significant reactivity with children's sera and a batch of HPV18 VLPs that had failed the quality control because of significant reactivity with sera from virginal women, were tested in parallel with heparin ELISA, ordinary ELISA and type-specific mAb capture ELISA. Control sera from children that had detectable reactivity with HPV16/11 hybrid VLPs in ordinary ELISA did not react in heparin-based ELISA, but some hybrid VLPs also had background reactivity in capture ELISAs. Control sera from virginal women that had some reactivity with a poor quality HPV18 VLP preparation in ordinary ELISA had no reactivity in heparin or capture ELISA, suggesting that certain VLP preparations expose cross-reactive epitopes that are not exposed on VLPs with heparin-binding ability. As the sensitivity was similar or only marginally affected by the use of heparin plates, use of heparin-coated plates may improve the type specificity of VLP-based ELISAs and reduce interassay variability attributable to variable quality of different VLP batches.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15604432     DOI: 10.1099/vir.0.80472-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.

Authors:  Dennis Dias; Jeff Van Doren; Sonela Schlottmann; Sheri Kelly; Derek Puchalski; Wanda Ruiz; Patricia Boerckel; Joseph Kessler; Joseph M Antonello; Tina Green; Martha Brown; Judith Smith; Narendra Chirmule; Eliav Barr; Kathrin U Jansen; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

2.  Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women.

Authors:  Ping Du; Sarah Brendle; Janice Milici; Fabian Camacho; John Zurlo; Neil Christensen; Craig Meyers
Journal:  J AIDS Clin Res       Date:  2015-03

3.  The use of human papillomavirus seroepidemiology to inform vaccine policy.

Authors:  Mark Schiffman; Mahboobeh Safaeian; Nicolas Wentzensen
Journal:  Sex Transm Dis       Date:  2009-11       Impact factor: 2.830

4.  Differential binding patterns to host cells associated with particles of several human alphapapillomavirus types.

Authors:  Tatevik R Broutian; Sarah A Brendle; Neil D Christensen
Journal:  J Gen Virol       Date:  2009-10-21       Impact factor: 3.891

5.  Clinicopathologic Implications of Complement Genetic Variants in Kidney Transplantation.

Authors:  Zhen Ren; Stephen J Perkins; Latisha Love-Gregory; John P Atkinson; Anuja Java
Journal:  Front Med (Lausanne)       Date:  2021-11-29

6.  ELISAs using human bocavirus VP2 virus-like particles for detection of antibodies against HBoV.

Authors:  Feng Lin; Wuxiang Guan; Fang Cheng; Ningmin Yang; David Pintel; Jianming Qiu
Journal:  J Virol Methods       Date:  2008-03-04       Impact factor: 2.014

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.